Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study;Gesundheitsökonomische Bewertung der Kombinationstherapie der rheumatoiden Arthritis mit Methotrexat und Etanercept auf der Basis der TEMPO-Studie.

Zeitschrift für Rheumatologie

Volumn 68, Issue 10, 2009, Pages 836-841

  Schulze Koops, H ^a   Deeg, M ^a   Runge, C ^a   Volmer, T ^a   Brecht, J G ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; METHOTREXATE; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG COST; ECONOMICS; GERMANY; HUMAN; MIDDLE AGED; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STATISTICS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; GERMANY; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; MIDDLE AGED; MONTE CARLO METHOD; NATIONAL HEALTH PROGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 77950949776     PISSN: None     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-009-0506-7     Document Type: Article

References (0)